CAMBRIDGE, Mass.--(BUSINESS WIRE)--Hydra Biosciences today announced that they have entered into an agreement with Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) for a joint collaboration to develop novel ion channel drugs. The deal focuses on Hydra’s research and development program for ion channel compounds that target the TRPA1 receptor, which is believed to have an important role in pain management.
